Hims & Hers reported third quarter 2026 results after the close on Monday, November 9, 2026. The quarter ended September 30, 2026. This was the first print to test our Hims & Hers report of October 15, 2026, which graded the company 64/100 Selective Positive at a $27.72 reference price. We published a preset scorecard on November 8 with six pass and fail gates. This article grades the print against those gates using the release and the full earnings call.
The short story is a growth print that hit its revenue guide and broke its margin line in the same quarter. The longer story is that the break was not an accident of one quarter. It is the branded model repricing itself in public, one mix point at a time.
The market graded faster than we can. Shares fell 11.8% on November 9 ahead of the release and 16.6% more on November 10 after it. The stock closed the week at $19.73, down 24% from the $26.00 close on the Friday before the print.
What did Hims & Hers actually report?
The short version
Revenue landed inside the guide and grew 49%, while the margin structure underneath it reset lower again.
- Revenue of $890.4M rose 49% and landed inside the $880M to $900M guide.
- Gross margin fell to 57% from 64% in Q2 and 74% a year earlier.
- Subscribers ended at 2.788M after the first sequential decline in this record.
- Revenue per subscriber rose 30% to $105 on branded and international mix.
- Adjusted EBITDA of $82.4M printed a 9% margin at the low end of the guide.
- Rest of world revenue of $233.3M reached 26% of the total.
The headline against the bar. The two lines management chose to guide both landed inside their ranges. Almost everything underneath them moved the wrong way. The table below scores the quarter against the guide Hims set on August 10 and against the consensus cluster our scorecard carried.
| Line | Company guide | Consensus | Printed | Year over year |
|---|---|---|---|---|
| Revenue | $880M to $900M | about $893M | $890.4M | +49% |
| Adjusted EBITDA | $75M to $95M | about $85M | $82.4M | +5% |
| Adjusted EBITDA margin | 9% to 11% | n/a | 9% | 13% a year ago |
| Gross margin | no guide | n/a | 57% | 74% a year ago |
| GAAP net income | no guide | n/a | loss of $33.0M | income of $15.8M |
| GAAP EPS | no guide | $0.06 to $0.07 | -$0.14 | $0.06 |
| Subscribers | no guide | n/a | 2.788M | +13% |
| Monthly revenue per average subscriber | no guide | n/a | $105 | +30% |
Consensus is the labeled cluster from our November 8 scorecard, drawn from Zacks and MarketBeat and Equibles. The adjusted EBITDA consensus of about $85M is a secondary tally published after the print. The company states no adjusted EPS, so the EPS line grades on the GAAP print against the consensus basis.
The margin walk. Cost of revenue rose to $381.2M from $156.9M a year earlier. That is a 143% increase against revenue growth of 49%. Revenue added $291.4M year over year and gross profit added $67.1M. About 23 cents of each added revenue dollar survived as gross profit. The walk below is the whole print in four rows.
| Quarter | Revenue | Gross profit | Gross margin |
|---|---|---|---|
| Q3 2025 | $599.0M | $442.1M | 74% |
| Q1 2026 | $608.1M | n/a | 65% |
| Q2 2026 | $753.2M | $480.8M | 64% |
| Q3 2026 | $890.4M | $509.2M | 57% |
The geography split. Rest of world revenue reached $233.3M, up 321%, and 26% of the total. The share was 17% in Q2 and 9% a year earlier. CFO Yemi Okupe put the Eucalyptus contribution at about $135M of the $233.3M. The rest of the international portfolio grew nearly 80% on its own. Q3 was the first full quarter with Eucalyptus inside the numbers, and that timing is the margin story as much as the growth story.
| Region | Q3 2026 revenue | Year over year | Share of total |
|---|---|---|---|
| United States | $657.1M | +21% | 74% |
| Rest of the world | $233.3M | +321% | 26% |
| Total | $890.4M | +49% | 100% |
GAAP, read separately. The GAAP lines carry the cost of the transition. The operating loss was $66.1M. The net loss was $33.0M after a $21.1M gain on the fair value of equity securities and a $13.2M tax benefit. Adjusted net income on the company's own reconciliation was $6.5M. The distance between the GAAP loss and the $82.4M of adjusted EBITDA is mostly stock compensation of $64.5M, depreciation and amortization of $38.2M, and acquisition and earnout costs of $35.4M.
The adjusted definition moved again. The company revised the definition of adjusted EBITDA in the quarter, for the third time in 2026. Foreign currency gains and losses are now excluded, following the first quarter change that moved restructuring charges into the exclusion list. Each revision is disclosed in the release. Each one also widens the gap between the adjusted line and the GAAP line, and the adjusted trend should be graded with that drift in mind.
Cash and the balance sheet. Operating cash flow was $65.4M against $148.7M a year earlier. Free cash flow was $26.0M against $79.4M, and the nine-month free cash flow total is $10.8M. Cash and short-term investments ended the quarter at $712.2M. The branded model shows up in working capital. Receivables rose to $427.8M from $32.1M at the end of 2025, and accounts payable rose to $515.7M from $143.3M. Deferred acquisition payables and earnout obligations total about $734M across the current and long-term lines. Goodwill now stands at $1.11B against total equity of $355.3M.
The deferral mechanic. Revenue in Q3 excluded $18M of weight loss membership revenue that was deferred into Q4. Management guided the full year deferral drag to at least $20M across revenue and adjusted EBITDA. The cash was collected in the quarter. Only the recognition moved.
How did the print grade against the preset gates?
The short version
Two gates passed, two graded partial, and two failed. The failures include the one gate the October report called decisive.
- Gross margin printed 57% against a fail line of 62% and a hold line of 64%.
- The full year adjusted EBITDA guide was cut by $33M at the midpoint.
- Revenue and adjusted EBITDA both landed inside their guided ranges.
- Subscribers fell sequentially while revenue per subscriber rose 30%.
- The print added no new legal charge, and the FTC widened its suit the next day.
| Gate | The preset bar | What printed | Grade |
|---|---|---|---|
| 1. Revenue vs guide | Revenue inside or above $880M to $900M | $890.4M, inside the range and just under the $893M consensus cluster | PASS |
| 2. Adjusted EBITDA vs guide | At or above $75M with margin inside 9% to 11% | $82.4M at a 9% margin, the low end of the guided range | PASS |
| 3. Gross margin | At or above about 64% to pass, below 62% to fail | 57%, a further leg down from 64% in Q2 and 74% a year earlier | FAIL |
| 4. Subscriber machine | Growth in the mid to high teens with revenue per subscriber at or above $90 | Growth of 13% with a sequential decline of about 103K, and revenue per subscriber of $105 | PARTIAL |
| 5. Full year guide | Revenue held at $3.1B to $3.3B and EBITDA held at $275M to $325M or raised | Revenue tightened to $3.13B to $3.15B and EBITDA cut to $257M to $277M | FAIL |
| 6. The overhangs | No new accrual or remedy on the FTC leg, and any Visa update scored as stated | No new legal charge in the quarter and no Visa update, with five states joining the FTC suit on November 10 | PARTIAL |
Gate 3, fail, and it is the print. The scorecard set two lines before the number existed. Gross margin at or above about 64% would hold the Q2 reset level and pass. Below 62% would print a second leg down and break the base case path. The print came in at 57%, five points under the fail line and seven points below Q2. There is no adjusted rescue available. Adjusted gross margin also printed 57% in the quarter because no restructuring charge sat inside cost of revenue this time.
What drove it. Management attributed the decline to the scaling of branded weight loss products in the international business. The mechanics are visible in the release. Q3 was the first quarter carrying three full months of Eucalyptus, against a partial quarter in Q2. Branded product carries pharmacy economics, and the international mix is now 26% of revenue. The driver is therefore structural rather than accidental. The growth engine and the margin drag are the same engine.
What management offered on recovery. One sentence in the outlook said gross margin declines should start to moderate as the pace of mix shift moderates. No target accompanied it and no timetable accompanied it. The fuller treatment of that exchange sits in the call section below. The October report built its base case on gross margin stabilizing in the mid-60s. That assumption did not survive this print, and the score in the final section moves because of it.
Gate 1, pass. Revenue landed inside the guide with growth accelerating for a second straight quarter. United States revenue grew 21%, up from 16% in Q2, and that acceleration happened while marketing was deliberately paced. The print sat just under the $893M consensus cluster. The gate graded the company guide rather than the cluster, and the guide was met.
Gate 2, pass at the low end. Adjusted EBITDA of $82.4M sits inside the $75M to $95M range. The margin of 9% sits at the floor of the guided 9% to 11% range and below the roughly $85M secondary consensus tally. Two qualifications belong on the record. The print excludes the $18M of deferred membership revenue, which would have lifted both the dollar figure and the margin. The definition of the measure also changed again in the quarter, as the first section noted.
Gate 4, partial. The monetization leg passed with room to spare. Revenue per subscriber printed $105 against a $90 bar, up 30% year over year. The growth leg failed. Subscriber growth slowed to 13% against a mid to high teens bar, and the count fell about 103K sequentially to 2.788M. Published tallies had put the subscriber expectation near 3.04M. Management attributed the decline to paced marketing in domestic weight loss and to brand migrations in international markets. A deliberate decline is still a decline, and the gate grades the count. One caveat cuts the other way on the $105 figure. The metric divides total revenue by average subscribers, and total revenue includes one-time purchases, so mix does part of the work in that number.
Gate 5, fail. The revenue guide was tightened rather than cut, with the midpoint moving from $3.20B to $3.14B inside the old range. The profit guide was cut outright. Adjusted EBITDA guidance fell from $275M to $325M to a range of $257M to $277M, a $33M cut at the midpoint. Management named the causes as aggressive strategic pricing and marketing in the United Kingdom and Germany, plus the membership deferral. The gate was written to fail on either guide being cut. Two revenue raises earlier in 2026 set a pattern, and this print broke the pattern on the line that matters more.
Gate 6, partial. The quarter itself passed the accrual test. The reconciliation shows no legal contingency charge in Q3, which leaves the nine-month charge at $62.5M and all of it booked in the first half. No settlement and no conduct remedy was disclosed. The week failed the spirit of the gate anyway. Five states joined the FTC suit the day after the print, and the Visa leg drew silence rather than an update. The next section grades both files in full.
What did the call add that the release did not?
The short version
The call explained the strategy behind every weak line and put numbers on almost none of the recovery paths.
- Management framed the subscriber decline and the guide cut as deliberate investment.
- The Lilly agreement brings Foundayo and Zepbound onto the platform into the new year.
- Eucalyptus contributed about $135M and the rest of international grew nearly 80%.
- The gross margin recovery question drew a pivot to EBITDA dollars rather than a path.
- No analyst asked about the FTC suit or the Visa program, and management raised neither.
Prepared remarks, the strategy frame. CEO Andrew Dudum built the remarks around one claim. Whoever owns the customer relationship wins, and every decision in the quarter served that ownership. The marketing pullback in domestic weight loss was presented as a choice made ahead of three arrivals. The Lilly assortment, the deeper Novo collaboration with CagriSema ahead, and new multi-month subscription plans all land around the new year. International brand consolidation under the Hims & Hers name was the second use of the pause. New category launches were the third.
Prepared remarks, the new facts. Several facts exist only on the call. The agreement with Eli Lilly expands access to Foundayo and Zepbound on the platform, which reverses the position our October report recorded, when Lilly refused the model entirely. Hers revenue is approaching $1B for the full year on the strength of dermatology and menopause. Testosterone is approaching a $100M annualized run rate after the launch of injectable and oral treatments, the company's first controlled substances. Peptides+ launches later in November with sermorelin and glutathione and NAD+ first. BPC-157 and TB-500 wait on the regulatory environment. Neuroscientist Andrew Huberman joined the board as a scientific and brand marketing adviser.
Prepared remarks, the finance walk. Okupe supplied the operating ratios the release leaves scattered. Marketing ran at 28% of revenue, an improvement of seven points in one quarter. Operations and support ran at 12% of revenue. Technology and platform investment ran at 8% of revenue in the largest engineering hiring quarter in company history. General and administrative expense improved five points on a GAAP basis to 17% of revenue. The international revenue expectation for 2026 rose to at least $650M from a prior $600M. Management also guided positive free cash flow for the full year 2026 and a well-positioned 2027 on the same measure.
The Canada evidence. The most concrete recovery evidence on the call came from Canada. Generic options became available there earlier this year, and average monthly orders have grown more than 50% since. Margins are also benefiting from the mix shift toward the lower-cost options, on management's account. Dudum extended the same arc to sexual health and hair in the United States, where generics and wider assortment eventually expanded margins per script. This is the bull mechanism for gross margin, stated plainly. It is also dated to a generic arrival that the United States has not yet had in weight loss.
Answered with numbers. The Eucalyptus split was answered directly, at about $135M of the $233.3M international total. The deferral was sized twice, at $18M in the quarter and at least $20M for the full year. The subscriber recovery was dated rather than sized. Marketing leans back in for the January acquisition season, and management expects subscriber growth to recover from the first quarter. The peptide rulemaking drew a process answer with a near date. The FDA comment period is aggregating now, and management expects a clearer rulemaking perspective within weeks.
Deflected, first, the subscriber split. Canaccord asked how much of the decline was lower acquisition spending and how much was retention. The answer returned to the deliberate pacing decision and the January plan. No retention figure was offered, which matches the company's standing practice of not disclosing churn. The question the gate needed answered stayed unanswered.
Deflected, second, the marketing dollar. Needham asked whether the pullback reflected a lower return on the incremental marketing dollar. Dudum answered with the assortment story and the January setup. No return figure and no customer acquisition cost was offered. The efficiency claim behind the 28% marketing ratio therefore rests on the ratio itself, which fell because spending was paced while revenue grew on mix.
Deflected, third, the decisive line. Morgan Stanley asked which drag was bigger near term and what could drive gross margin back up. Okupe answered the first half with the Eucalyptus timing point. On recovery, he said the team would come back to the question, and then framed adjusted EBITDA dollars as the focus instead. He noted the quarter printed one of the highest adjusted EBITDA dollar totals in company history. That may be true and it is not a gross margin path. The single number our report calls decisive drew the call's clearest deflection.
What the call never touched. No analyst asked about the FTC lawsuit. No analyst asked about the Visa monitoring program. Management raised neither topic in the prepared remarks. For a company whose two named overhangs are a federal suit and a card network program, that silence is a choice, and the grading records it as one.
Where does the regulatory overhang stand now?
The short version
The print held the legal accrual flat, and the FTC widened the case the day after the print.
- No new legal contingency charge printed in Q3, leaving the nine-month charge at $62.5M.
- The FTC amended its complaint on November 10 and added five states as co-plaintiffs.
- The amended complaint raised the count total from nine to sixteen.
- The Visa program drew no mention in the release or on the call.
The FTC file inside the print. On the numbers, nothing moved. The adjusted EBITDA reconciliation records no legal contingency charge in the third quarter. The nine-month charge stands at $62.5M, and all of it was booked in the first half of the year. No settlement was announced and no conduct remedy was disclosed. The hearing on the motion to dismiss stands on January 7, 2027 on the court reporting our scorecard carried. Graded on the print alone, the overhang was quiet.
The FTC file the day after. On November 10, the FTC filed an amended complaint in the Northern District of California. Arizona and Florida and Nebraska and Ohio and Wisconsin joined as co-plaintiffs alongside Utah and California, the last acting through Los Angeles County Counsel. The count total rose from nine to sixteen, and the commission vote to authorize the filing was 2-0. The amended complaint also put new figures into the public record. It cites about 14 million customer email addresses uploaded to Meta and roughly 8 million tracking events tied to medical treatments. Hims responded that it will fight what it calls follow-on claims. None of the allegations has been tested in court.
How to grade the widening. The scorecard named three fail triggers for this gate. They were a materially larger accrual, a settlement with structural remedies, and any DOJ signal. None of the three has occurred. What occurred instead is breadth. Seven states now stand behind a complaint whose billing and cancellation counts describe the same checkout the growth model runs on. A wider plaintiff bench widens the remedy surface without changing the accrual today. That is an escalation of the file, and it is not yet a change in its price.
The Visa file. Neither the release nor the call mentioned the Visa Acquirer Monitoring Program. Our scorecard rule for silence is explicit. Silence leaves the last verified status in place, and that status dates to August 2026. The company was enrolled in the program at an $8 per dispute surcharge, with exit requiring three straight months below a 1.5% dispute rate. We found no November update in the release or the call or the coverage of either. The August status is therefore the current status, and it is not an exit.
The two files measure the same checkout. The amended complaint's billing and cancellation counts and the Visa dispute rate are two readings of one customer experience. The company's own changes this quarter move in the direction both files point. Multi-month subscription plans change the billing shape that generated the disputes, and $18M of membership revenue moved out of the quarter as recognition follows the new plans. Whether those changes lower the dispute rate is a question for the next two quarters. This print does not answer it.
What are the bears right about?
The short version
The bears own the margin structure, the adjusted to GAAP gap, and the subscriber count.
- Gross margin has fallen from 74% to 57% across the reported quarters of the reset.
- Stock compensation of $64.5M in one quarter sits between the GAAP loss and adjusted EBITDA.
- The adjusted EBITDA definition has been revised three times in 2026.
- Subscribers fell sequentially while marketing was deliberately paced.
- Receivables of $427.8M show the working capital price of branded distribution.
The margin structure is the model now. Bears do not need to forecast a margin problem. The reported path runs 74% to 65% to 64% to 57% across the reset quarters. Branded weight loss is the growth engine in both geographies, and it carries pharmacy economics by construction. Management's recovery mechanisms are real and they are all dated later. Generic arrivals, category diversification overseas, and verticalized supply chains are 2027 and beyond stories. The Q4 guide embeds the same structure, with adjusted EBITDA of $70M to $90M at an 8% to 10% margin.
The adjusted to GAAP gap is wide and widening. The GAAP net loss was $33.0M in the quarter and $211.4M across nine months. Adjusted EBITDA over the same nine months was $187.0M. Stock compensation alone was $64.5M in the quarter and $143.5M across nine months. Even the company's adjusted net income line shows a nine-month loss of $57.9M. Adjusted general and administrative expense rose to $91.7M from $50.1M a year earlier, so the expansion costs show through even after the exclusions. The definition revisions compound the problem. A measure that has been redefined three times in a year is a moving yardstick, and the GAAP column is the one that does not move.
The subscriber count answered the CAC question sideways. Marketing fell to 28% of revenue from 39% a year earlier. Management frames the drop as deliberate pacing ahead of the January season and the new assortment. The count fell by about 103K in the same quarter, and management guided a further possible quarter of headwinds. Customer acquisition cost is not disclosed, so the print cannot prove efficiency in either direction. What it proves is narrower. When the company stopped buying growth at the old pace, the count shrank. The Q4 plan leans back into aggressive marketing in the United Kingdom and Germany, and the January plan leans back in at home. The efficiency test is therefore still ahead of the company, not behind it.
The soft figures. Revenue per subscriber of $105 is computed on total revenue, which includes one-time purchases, so mix does part of the work. Operating cash flow fell 56% year over year to $65.4M. Receivables of $427.8M against $32.1M at the end of 2025 show what branded distribution does to working capital, even with a receivables facility behind it. Goodwill of $1.11B now exceeds total equity of $355.3M by a wide margin after the Eucalyptus consolidation. None of these figures breaks the story alone. Together they describe a company whose growth is getting more expensive to carry.
The Q4 guide confirms the shape. Fourth quarter revenue is guided to $875M to $895M. The midpoint of $885M is a sequential decline from the $890.4M just printed, and post-print tallies put the consensus it trails near $955M. A company growing 49% year over year is guiding a down quarter sequentially, by choice, into its strongest seasonal window. Bears are right to ask what the choice costs if the January assortment does not convert.
What changes from here?
The short version
Our score falls from 64 of 100 to 52 of 100, and the rating moves from Selective Positive to Neutral.
- The decisive gate failed through its preset fail line.
- The full year EBITDA guide was cut while revenue was only tightened.
- Revenue growth of 49% and positive free cash flow keep the score out of the 40s.
- The FY2029 base build loses its margin leg and will be rebuilt in the package refresh.
The score position. Our Hims & Hers score falls to 52/100 Neutral from 64/100 Selective Positive. The reasoning ties to the gates rather than to the stock's 24% weekly fall. The October report wrote its own grading rule in advance. Quarterly gross margin is the single number that validates or breaks the base case. The number printed 57% against a preset fail line of 62%. The full year guide gate failed beside it, and the subscriber gate printed the first sequential decline in this record. A hold would require the decisive gate to survive. It did not.
Why the score stops at 52. Two gates passed cleanly. Revenue grew 49% with domestic acceleration, and adjusted EBITDA landed inside its guide. Free cash flow stayed positive and the balance sheet carries $712.2M of cash and investments. The FTC fail triggers named in the scorecard did not fire, and the Lilly agreement removed a moat debit our report carried. Those facts keep the business graded as a going growth story with a broken margin path, rather than as a broken business.
The scenario frame. The FY2029 scenarios from the October report stand at bear $12, base $48, and bull $100. The base build paired revenue of $5.2B with an adjusted EBITDA margin of 15%. Its two legs are now tracking in opposite directions. Revenue runs ahead of the build, with the 2026 guide midpoint at $3.14B. The margin leg runs at the bear build's level, with the 2026 guide implying an 8% to 9% margin against the bear case's 8%. The bear case also assumed an FTC remedy with teeth, and that half has not printed. The base case as built no longer stands, and the package refresh will rebuild the scenarios on a lower gross margin plateau.
The guide position after the print. Full year 2026 revenue is guided to $3.13B to $3.15B with adjusted EBITDA of $257M to $277M. The fourth quarter is guided to revenue of $875M to $895M and adjusted EBITDA of $70M to $90M. International revenue is expected to reach at least $650M for the year, up from the prior $600M expectation. Positive free cash flow is guided for 2026 and 2027. The 2030 company targets of $6.5B of revenue and $1.3B of adjusted EBITDA were not addressed on the call.
What would change the score. The score rises if gross margin recovers toward the low 60s across two quarters while subscriber growth returns and the FTC file closes without conduct terms. It falls further if Q4 gross margin prints at or below 57% again, if the EBITDA guide is cut again with the Q4 print, or if the FTC case produces a remedy with conduct terms. Those lines are dated by the checkpoint table below.
| Checkpoint | Date or window | The line to grade |
|---|---|---|
| Peptides+ launch | Late November 2026 | Sermorelin and glutathione and NAD+ live on the platform, with BPC-157 and TB-500 gated on FDA rulemaking |
| FTC motion to dismiss hearing | January 7, 2027 | Dismissal or survival of the sixteen counts, and any conduct signal from the court |
| Q4 2026 print | February 2027, expected | Revenue of $875M to $895M and adjusted EBITDA of $70M to $90M, with gross margin graded against the moderation claim |
| Subscriber recovery | Q1 2027 print | Growth resuming as marketing leans into the January season with the Lilly and Novo assortment live |
| International delivery | Fiscal 2026 close | At least $650M of international revenue against the raised expectation |
| Visa status | Any quarter | A stated exit from the monitoring program, or continued silence |
The growth story and the margin story are now the same story told at two speeds. Revenue is compounding at 49% on a model whose gross margin has reset to 57%. The next two prints decide which of those two numbers the multiple follows.
Frequently asked questions
Did Hims & Hers beat its Q3 2026 guidance?
On revenue and adjusted EBITDA, yes. Revenue of $890.4M landed inside the $880M to $900M guide and adjusted EBITDA of $82.4M landed inside the $75M to $95M guide. Gross margin and the full year EBITDA guide are where the print failed, and GAAP EPS of negative $0.14 missed the positive consensus cluster.
Why did Hims & Hers gross margin fall to 57%?
The mix moved to branded weight loss products, led by the first full quarter of Eucalyptus in international markets. Cost of revenue rose 143% year over year against revenue growth of 49%. Of the $291.4M of added revenue, only $67.1M survived as added gross profit.
What would change the DalalBytes score on Hims & Hers?
The score falls to 52 of 100 Neutral after the decisive gross margin gate failed. It rises if gross margin recovers toward the low 60s across two quarters while subscriber growth returns. It falls further on an FTC remedy with conduct terms or another cut to the EBITDA guide.
Disclosures
Research and opinion, not investment advice. The author holds a long position in Hims & Hers (HIMS). Positions may change without notice. Figures are drawn from the Hims & Hers third quarter 2026 earnings release of November 9, 2026 and the earnings call held the same day, unless labeled otherwise. The FTC amendment is drawn from the Federal Trade Commission release of November 10, 2026. Consensus figures are the labeled cluster carried in the DalalBytes preset scorecard of November 8, 2026, with post-print tallies labeled where they appear. Share prices are market data provider figures for the sessions named. DalalBytes research on Hims & Hers: investment report and five-pillar analysis.
© 2026 DalalBytes Research ยท For educational purposes only. Not investment advice.